Adjuvant HoldingsLtd Dirección

Dirección controles de criterios 2/4

El CEO de Adjuvant HoldingsLtd's es Yutaka Nakamura, nombrado en Jan 2021, tiene una permanencia de 3.25 años. posee directamente un 22.42% de las acciones de la empresa, con un valor de ¥1.54B. La antigüedad media del equipo directivo y de la junta directiva es de 8 años y 2.8 años, respectivamente.

Información clave

Yutaka Nakamura

Chief Executive Officer (CEO)

n/a

Compensación total

Porcentaje del salario del CEO	n/a
Permanencia del CEO	3.6yrs
Participación del CEO	21.3%
Permanencia media de la dirección	8.3yrs
Promedio de permanencia en la Junta Directiva	3.2yrs

Actualizaciones recientes de la dirección

Recent updates

CEO

Yutaka Nakamura (78 yo)

3.6yrs

Permanencia

Mr. Yutaka Nakamura has been Chairman of the Board at Adjuvant Cosme Japan Co., Ltd. since June 16, 2016 and serves as President. Mr. Nakamura has been President at K.K.Adjuvant since 1992. Mr. Nakamura E...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Yutaka Nakamura	Chairman & President	3.6yrs	sin datos	21.28% ¥ 1.4b
Hideo Nakagawa	GM of Administration & Director	13.8yrs	sin datos	0.17% ¥ 11.5m
Takeshi Fujiwara	GM of Sales & Director	3.4yrs	sin datos	0.050% ¥ 3.4m
Junko Tanaka	Senior MD & Director	13.1yrs	sin datos	14.05% ¥ 955.4m

8.3yrs

Permanencia media

71.5yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de 4929 es experimentado (8 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Yutaka Nakamura	Chairman & President	33.3yrs	sin datos	21.28% ¥ 1.4b
Hideo Nakagawa	GM of Administration & Director	13.2yrs	sin datos	0.17% ¥ 11.5m
Takeshi Fujiwara	GM of Sales & Director	1.4yrs	sin datos	0.050% ¥ 3.4m
Junko Tanaka	Senior MD & Director	no data	sin datos	14.05% ¥ 955.4m
Masamitsu Minami	Independent Outside Director	3.2yrs	sin datos	0.049% ¥ 3.3m
Junji Mimura	Independent Outside Director	3.2yrs	sin datos	0.050% ¥ 3.4m
Kiyoharu Kageta	Independent Outside Director	3.2yrs	sin datos	0.025% ¥ 1.7m
Hirokazu Ohshima	Director	1.4yrs	sin datos	sin datos

3.2yrs

Permanencia media

71.5yo

Promedio de edad

Junta con experiencia: La junta directiva de 4929 se considera experimentada (3 años de antigüedad promedio).

Adjuvant HoldingsLtd Dirección

Dirección controles de criterios 2/4

Información clave

Actualizaciones recientes de la dirección

Adjuvant Holdings Co.,Ltd., Annual General Meeting, Jun 13, 2024

Less than half of directors are independent

Less than half of directors are independent

Adjuvant Holdings Co.,Ltd., Annual General Meeting, Jun 16, 2022

Recent updates

First quarter 2025 earnings released: EPS: JP¥1.63 (vs JP¥5.39 loss in 1Q 2024)

Adjuvant Holdings Co.,Ltd. to Report Q1, 2025 Results on Jul 19, 2024

Full year 2024 earnings released: JP¥12.38 loss per share (vs JP¥50.38 profit in FY 2023)

Adjuvant Holdings Co.,Ltd., Annual General Meeting, Jun 13, 2024

Full year 2024 earnings released: JP¥12.38 loss per share (vs JP¥50.38 profit in FY 2023)

Upcoming dividend of JP¥24.00 per share

Adjuvant Holdings Co.,Ltd. to Report Fiscal Year 2024 Results on Apr 19, 2024

Third quarter 2024 earnings released: EPS: JP¥15.50 (vs JP¥15.88 in 3Q 2023)

Adjuvant Holdings Co.,Ltd. to Report Q3, 2024 Results on Jan 19, 2024

Second quarter 2024 earnings released: JP¥12.13 loss per share (vs JP¥1.13 profit in 2Q 2023)

New major risk - Dividend sustainability

New minor risk - Profit margin trend

First quarter 2024 earnings released: JP¥5.39 loss per share (vs JP¥24.74 profit in 1Q 2023)

Full year 2023 earnings released: EPS: JP¥50.38 (vs JP¥49.11 in FY 2022)

Adjuvant Holdings Co.,Ltd. to Report Q2, 2024 Results on Oct 20, 2023

Full year 2023 earnings released: EPS: JP¥50.38 (vs JP¥49.11 in FY 2022)

Upcoming dividend of JP¥24.00 per share at 2.3% yield

Third quarter 2023 earnings released: EPS: JP¥15.88 (vs JP¥19.89 in 3Q 2022)

Adjuvant Holdings Co.,Ltd. to Report Q3, 2023 Results on Jan 20, 2023

Less than half of directors are independent

Second quarter 2023 earnings released: EPS: JP¥1.13 (vs JP¥10.76 in 2Q 2022)

Adjuvant Holdings Co.,Ltd. to Report Q2, 2023 Results on Oct 21, 2022

First quarter 2023 earnings released: EPS: JP¥24.74 (vs JP¥10.76 in 1Q 2022)

Full year 2022 earnings released: EPS: JP¥49.11 (vs JP¥17.78 in FY 2021)

Adjuvant Holdings Co.,Ltd. to Report Q1, 2023 Results on Jul 22, 2022

Less than half of directors are independent

Adjuvant Holdings Co.,Ltd. (TSE:4929) announces an Equity Buyback for 50,000 shares, representing 0.62% for ¥52.5 million.

Adjuvant Holdings Co.,Ltd., Annual General Meeting, Jun 16, 2022

Upcoming dividend of JP¥24.00 per share

Adjuvant Holdings Co.,Ltd. to Report Fiscal Year 2022 Results on Apr 22, 2022

Now 20% undervalued after recent price drop

Third quarter 2022 earnings: Revenues and EPS in line with analyst expectations

Second quarter 2022 earnings released: EPS JP¥10.76 (vs JP¥11.14 loss in 2Q 2021)

First quarter 2022 earnings released: EPS JP¥10.76 (vs JP¥0.63 loss in 1Q 2021)

Full year 2021 earnings released: EPS JP¥17.78 (vs JP¥28.51 loss in FY 2020)

Full year 2021 earnings released: EPS JP¥21.79 (vs JP¥28.51 loss in FY 2020)

Upcoming Dividend of JP¥24.00 Per Share

New 90-day high: JP¥1,099

An undisclosed buyer entered into a share transfer agreement to acquire 90% stake in EXCEED system. Co., Ltd., from Adjuvant Cosme Japan Co.,Ltd. (TSE:4929).

New 90-day high: JP¥1,072

Third quarter 2021 earnings released: EPS JP¥24.78

New 90-day high: JP¥1,043

Adjuvant Cosme Japan Co.,Ltd. to Report Q3, 2021 Results on Jan 22, 2021

Adjuvant Cosme Japan Co.,Ltd. to Report Q2, 2021 Results on Oct 23, 2020

CEO

Permanencia

Equipo directivo

Permanencia media

Promedio de edad

Miembros de la Junta

Permanencia media

Promedio de edad